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ReviewGlossary
Acidic/basic fibroblast growth factor (a/bFGF): potent mitogens and chemoat-
tractants for vascular endothelial cells, dermal fibroblasts and epidermal
keratinocytes.
Allograft: transplantation of cells, tissues, or organs from a nonidentical donor
of the same species into a recipient.
Autograft: transplantation of cells, tissues, or organs from one part of the body
to another in the same individual.
Chemoattractant: a chemical substance that induces a cell or organisms to
migrate towards it.
Colony stimulating factor-1 (CSF-1): a haematopoietic GF involved in the
proliferation, differentiation, and survival of monocytes, macrophages, and
bone marrow progenitor cells.
Cosmesis: the preservation or restoration of bodily beauty.
Epidermal growth factor (EGF): implicated in keratinocyte migration, fibroblast
proliferation and differentiation, and granulation tissue formation.
Human adipose-derived stem cells (hADSCs): a source of mesenchymal SCs
that have shown a potential for therapeutic vascularisation due to the
production of angiogenic GFs.
Hyaluronic acid (HA): a major component of human skin extracellular matrix.
Insulin-like growth factor-1 (IGF-1): a glycoprotein mainly produced in the liver
but also expressed by fibroblasts. High concentrations within wound beds
accelerate keratinocyte migration and proliferation.
Keratinocyte growth factor (KGF): member of the FGF family (FGF-7) and
involved in epidermal keratinocyte proliferation. In 2004, human recombinant
KGF (Kepivance Biovitrum, USA) was FDA approved for use in radiotherapy-
induced oral mucositis in the treatment of epithelial cancer.
Mitogen: a chemical substance that stimulates cell division.
Platelet-derived growth factor (PDGF): a chemoattractant for fibroblasts,
neutrophils, and monocytes, which promotes production of new ECM by
fibroblasts. FDA approved (Regranex) since 1997.
Primary cutaneous anaplastic large cell lymphoma (PCALCL): a form of non-
Hodgkin’s lymphoma.
Transforming growth factor-b (TGF-b): a key mediator for fibroblast migration
and proliferation, granulation tissue formation, and increased collagen
synthesis and neovascularisation.
Tumour necrosis factor-b (TNF-b): a cytokine expressed by a multitude of cells
and involved in attracting fibroblasts.Skin wounds are a major social and financial burden.
However, current treatments are suboptimal. The gradual
comprehension of the finely orchestrated nature of inter-
cellular communication has stimulated scientists to inves-
tigate growth factor (GF) or stem cell (SC) incorporation
into suitable scaffolds for local delivery into wound beds in
an attempt to accelerate healing. This review provides a
critical evaluation of the status quo of current research
into GF and SC therapy and subsequent future prospects,
including benefits and possible long-term dangers asso-
ciated with their use. Additionally, we stress the impor-
tance of a bottom-up approach in scaffold fabrication to
enable controlled factor incorporation as well as produc-
tion of complex scaffold micro- and nanostructures re-
sembling that of natural extracellular matrix.
A multimodal cocktail for skin regeneration
Skin serves the onerous function of protecting our internal
organs and tissues from external, potentially dangerous
insults for a lifetime. Such temporal demands require not
only impeccable integrity, but also mechanical strength
and durability. Box 1 provides an overview of the skin’s
normal structure. Loss of large parts of this barrier, be it
related to illness or injury, renders the individual suscep-
tible to disability or death. The World Health Organisation
(WHO) estimates that, annually, over 300 000 deaths are
attributable to fire-related burn injuries with millions
more suffering from the partly devastating physical and
emotional consequences thereof [1]. A further 6.5 million
individuals suffer from chronic skin ulcers caused by pro-
longed pressure, venous stasis, or diabetes mellitus [2]. A
more detailed account of normal wound healing is given in
Box 2. Box 3 provides details on the currently acceptable
management of thermal wounds. The holistic goals of
modern cutaneous wound care consist of rapid wound
excision and closure with a functionally intact and aes-
thetically pleasing outcome. Currently available treatment
options are lacking in establishing both functional and
cosmetic satisfaction. Thus, combined with the burden of
pain and the currently suboptimal therapy methods, the
overall onus of cutaneous wounds appears vast. It seems ofCorresponding authors: Yildirimer, L. (e.yildirimer@ucl.ac.uk);
Seifalian, A.M. (a.seifalian@ucl.ac.uk).
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cept of aiming to replace lost skin tissue, and rather focus
on promoting the regeneration of wounded tissues by
stimulating the innate ability of the skin for self-renewal.
Wound contracture and scarring, properties that can mis-
leadingly be thought accountable for faster wound healing,
should be avoided in terms of wound regeneration. The
gradual understanding of the biological processes involved
in wound healing has opened the gates for developing smart
bioconstructs that actively promote tissue regeneration viaVascular endothelial growth factor (VEGF): a key regulator in angiogenesis
during physiological processes such as wound healing but also thought to
nourish pathological conditions including cancer.
Wound contraction/contracture: although an integral stage in the wound
healing process, prolonged contraction results in unsightly and thickened scars.
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Box 1. The skin: beyond a first glance
Skin is the outermost covering of human beings and the largest organ
of the body, encompassing the entire body surface. It has a complex
three-layered structure (Figure I) which, under physiological circum-
stances, is intrinsically self-renewable, so that a new layer of skin
develops every 2–3 weeks while continuously shedding the older top
layers.
The three layers (Figure I), from outermost to innermost are: (i)
epidermis: multiple, ever renewing layers of keratinocytes; (ii) dermis:
separated from the epidermis at the dermal–epidermal junction
(basement membrane); and (iii) hypodermis: mainly made up of
adipose tissue and collagen.
Skin appendages such as hair follicles, sebaceous glands and sweat
glands are numerously intermingled along blood vessels, nerve
endings, and pressure and touch receptors. Regional variations exist
regarding skin thickness, distribution of skin appendages, and
melanocyte density. Skin mainly functions as a protecting interface,
physically shielding internal organs and tissues from external insults.
Once the external barrier is breached, innate surveillance mechan-
isms set off a cell-signalling cascade to limit pain, control infection,
and accelerate wound healing naturally, ultimately creating a scar.
However, extensive wounds such as those associated with full-
thickness burns rarely, if ever, heal spontaneously and thus require an
external means of protection, be it temporary or permanent, to
stimulate not only wound healing, but scarless self-regeneration.
Current conventions hold that tissue-engineered skin constructs
should resemble native skin both anatomically and functionally.
Epidermis 
Dermis
Hair follicle
Sweat gland
Blood vessels 
Nerves
Hypodermis
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Figure I. An illustration of human skin showing the three constituting layers and skin adnexae.
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folds, as well as the incorporation of cell-signalling elements
such as GFs and SCs. Here, we review and critically
appraise current research efforts concerned with dermal
regeneration scaffolds incorporating bioactive elements to
promote neovascularisation and tissue regeneration. We
also touch upon the most recent advances in the field of
nanoscaled tissue engineering because cellular behaviour is
significantly influenced by the surface nanotopography of
the scaffold that promotes cellular adherence, differentia-
tion, and proliferation, mimicking natural extracellular
matrix (ECM) [3].
Current state of tissue-engineered skin substitutes
The pressing need for more suitable wound dressings has
spurred on the search for alternative skin substitutes that
actively promote wound regeneration. The era of dermal
tissue engineering was heralded three decades ago with a
bilayered and biocompatible dermal scaffold based on a
bovine collagen matrix, which successfully induced the
synthesis of a neodermis [1]. This novel bioconstruct revo-
lutionised current burns practice and even today, Integra
is often used as the gold standard in severe full-thicknessburns that are not amenable to autograft (see Glossary)
harvest, due to immediate availability, skin infiltration
rates similar to that of skin allografts (85% versus 95%)
and adequate cosmetic results [2].
Clinically available and novel skin substitutes can be
broadly divided into epidermal, dermal, and dermoepider-
mal (composite) tissue-engineered constructs [4]. A multi-
tude of choices and potential alternatives for tissue-
engineering skin constructs exist and, in fact, numerous
substitutes are being investigated for human usage; some
of them already commercialised (Table 1).
The current lack of more sophisticated and superior skin
alternatives requires a focus on regeneration rather than
replacement. Current research is increasingly integrating
the concept of engineering dermal scaffolds that actively
promote regeneration by incorporating SCs and external
GFs to recreate a favourable cellular microenvironment.
SCs have been central to the field of regenerative medicine
for over three decades due to an ability to induce their
differentiation into any cell type with subsequent cell-
specific GF and cytokine release to enhance angiogenesis
[3]. This approach is motivated by the understanding that
numerous cell–cell and cell–ECM cues are required to639
Table 1. Characteristics of the ideal skin substitute
Dermoepidermal substitute (composite) Dermal substitute Epidermal substitute Ref
Cadaveric
skin (nonprofit
skin banks)
Karoskina Apligrafa Alloderma SureDerma Integraa Dermagrafta MySkina CellSpraya
Patient safety Potential for viral
transmission
Immune rejection
Potential for viral
transmission
Immune rejection
Potential for
viral
transmission
Potential for viral
transmission
Potential for viral
transmission
n/ab Potential for viral
transmission
Autologous
keratinocytes are
cocultured with
irradiated murine
cells
n/a [2]
Scaffold
degradability
Rejection rather than
degradation
Rejection rather
than degradation
1–2 months Incorporates into
wound bed
Incorporates into
wound bed
Half-life, 30 days Degrades by
hydrolysis
<29 days n/f [81]
Duration of
cover
Temporary Temporary Temporary Permanent Permanent Semi-permanent Temporary Permanent Permanent [4]
Neodermis
formation
Dermis revascularises
and integrates into the
wound bed. The
epidermis is rejected
3–4 weeks post-
transplantation
Dermis
revascularises and
integrates into the
wound bed. The
epidermis is
rejected 3–4 weeks
post-
transplantation
Delivers ECM
components,
cytokines and
GF to the
wound
Repopulated by
host cells, i.e.,
incorporates into
host tissue
Repopulated by
host cells, i.e.,
incorporates into
host tissue
Neodermis
formation
complete in
15–20 days
Scaffolds
degrade over
20–30 days.
Fibroblasts
simultaneously
produce ECM
components and
GF
Only applicable in
partial-thickness
and graft donor
side wounds, but
not in full-
thickness wounds
Only applicable
in partial-
thickness and
graft donor side
wounds, but not
in full-thickness
wounds
[82–85]
Shelf life 7–10 days if fresh.
Unlimited if
lyophilised
Unlimited if
lyophilised
5–10 days 2 years Up to 2 years 2 years Up to 6 months 3 days n/f [4]
Cost (/cm2)
(in 2007)
donated £0.60 £14.20 £5.90 n/f £3.32 £7.14 n/f n/f [2]
Mechanical
stability
Lyophilisation
improves mechanical
stability significantly
Lyophilisation
improves
mechanical
stability
significantly
Requires
delicate
handling
Stable due to
presence of
basement
membrane.
No adverse
information
regarding fragility
and manual
handling
Easy handling Easy handling Easy handling and
application due to
a silicone support
layer
Very fragile and
difficult to
handle
[4,86]
Scaffold
vascularisation
(i.e., ‘take’)
Cadaveric allografts
take initially, i.e.,
vascularisation is
observed, however,
subsequent graft
rejection requires its
eventual removal
Takes initially, i.e.,
vascularisation is
observed,
however,
subsequent graft
rejection requires
its eventual
removal
Take rates
depend on the
type of wound
and are very
variable
ranging from
16 to 41%
Uncertain rates of
vascularisation
No adverse
information
regarding delayed
or failed graft take
Takes relatively
long time for
vascularisation
(10–14 days)
Take is facilitated
by fibrovascular
in growth and re-
epithelialisation
and wound
closure by
keratinocytes
migration from
wound edges
Cannot be used for
full-thickness
wounds as dermal
component
missing
Uncertain rate
of take as it
depends on
cell–cell and
cell–ECM
adhesion rather
than
vascularisation.
Higher risk of
bacterial
contamination
leading to graft
loss
[75]
No. of stages
necessary for
completion
Multiple because
cadaveric grafts
require eventual
replacement
Multiple because
cadaveric grafts
require eventual
replacement
One-stage
process but
needs
cografting with
autologous
epithelial cells
in full-thickness
burns
One-stage
process (using
ultrathin split-
thickness graft)
Two-stage process
(using split-
thickness graft)
Two-stage
process (using
split-thickness
graft)
Two-stage
process if used in
burn injuries
(using split-
thickness graft)
Up to 12 individual
applications
One-stage
process
[4]
aCommercialised product.
bn/a, not applicable; n/f, not found.
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and tissues [5]. Furthermore, naturally occurring ECM
components, as well as physiological molecules involved
in wound healing, have dimensions in the nanometre range
(1–100 nm), thus suggesting a significant and exploitable
potential for ‘nanoengineered’ particle delivery vehicles.
For example, nanoparticles could be used to create advan-
tageous surface nanostructures or nanotopography resem-
bling natural structures, and further seeded with SCs or
functionalised with GFs [6], cytokines, and peptides [7].
Bioengineering ‘smart’ scaffolds for skin regeneration: a
bottom-up approach
The ultimate purpose of tissue-engineered skin grafts is to
enable complete and natural, albeit accelerated, wound
regeneration. A 3D supporting framework should serve as
a template for tissue regeneration while simultaneously
preventing wound bed contraction throughout the first
stages of healing [8]. The framework, or scaffold, should
further serve as a platform for cellular localisation, adhe-
sion, and differentiation, as well as guide the development
of new functional tissues [9]. A focus on the multitude of
different scaffold materials and fabrication techniques is
beyond the scope of this article but has been extensively
reviewed elsewhere [10]. Scaffold materials may be of
natural, synthetic, or composite origin and engineered
using a multitude of approaches including porogen leach-
ing, electrospinning, molecular self-assembly, and phase
separation. The mixing of materials of different classes to
obtain composite scaffolds seems particularly promising
because individual limitations of single material scaffolds
(e.g., poor mechanical properties) are often overcome by the
composite nature [11]. The ideal skin regeneration scaffold
should actively direct tissue formation and prevent scar-
ring. Thus, much focus has been channelled into creating
suitable biomimetic surface micro- and nanostructures
that can act as delivery vehicles for SCs or GFs. The
synergistic tissue regenerating effects of a smart scaffold
cocktail comprising (i) favourable scaffold surface patterns,
(ii) GFs, and (iii) SCs have the realistic potential of over-
coming current barriers and enabling fast and complete
skin regeneration.
During natural wound healing, dynamic and reciprocal
interactions between components of the ECM and sur-
rounding cell-signalling molecules are responsible forBox 2. Normal wound healing
Wounds are defined as breaks in the continuity of the structure of the
skin, usually resulting from physical trauma and leading to either
temporary or terminal loss of function. Healing is a complex dynamic
process that results in the restoration of anatomic continuity and
function (Figure I). It consists of four distinct but overlapping entities
that depend on complex and finely orchestrated cell-signalling events.
Haemostasis:
(i) Triggered post-injury by platelets within the wound bed.
(ii) Platelets interact with ECM to activate clotting cascade.
(iii) Resultant blood clot provides a platform for cell migration.
Inflammation:
(i) Triggered by PDGF and TGF-b released by platelets.
(ii) Neutrophils and monocytes are recruited to phagocytose foreign
material/pathogens.the expression of GFs and cytokines. These interactions
elicit cellular responses that ultimately lead to new tissue
formation. Overwhelming activation of the inflammatory
system and prolific recruitment of contractile cells is
thought to stem from prehistoric adaptations of human
skin to close irregular and often contaminated wounds as
rapidly as possible, to prevent microorganism invasion and
potentially lethal infections [12]. Unfortunately, this re-
sponse typically leads to scar formation, often resulting in
disfigurement and functional disability. Nowadays, some
wounds are closed aseptically using sutures that obviate
the need for a vigorous contractile response, creating more
time for complete tissue regeneration. Here, external mod-
ulation of cell-signalling events via a finely tuned delivery
of GFs or SCs is thought to alter the wound environment,
enabling orderly regeneration. Modifying the micro- and
nanoenvironment and surface architecture of the scaffold,
termed nanotopography, actively influences cell migration,
proliferation, and differentiation.
In the following sections, we focus on discussing incor-
poration of various GFs involved in wound healing into
scaffolds and the possibilities of exploiting the latest SC
technologies to accelerate skin regeneration. Potential
advantages of cutting-edge nanoengineered scaffolds over
macrosized skin substitutes as 3D stimulatory platforms
for cellular growth and skin regeneration are highlighted.
Overall, we support the argument that a bottom-up ap-
proach (i) enables tight control over important micro- and
nanostructures within scaffold architecture; and (ii) facil-
itates incorporation of appropriate concentrations of bio-
active factors as well as SCs.
GF functionalised skin-regeneration scaffolds
Epidermal growth factor (EGF)
EGF is implicated in keratinocyte migration, fibroblast
proliferation and differentiation, and granulation tissue
formation. EGF significantly enhances wound healing
[13] as well as the tensile strength of the resultant ECM
[14]. Prolonged exposure to EGF yielded a 200% increase in
tensile strength when liposome-encapsulated EGF was de-
livered into murine dorsal cutaneous wounds [15]. Similar-
ly, EGF contained within a gelatine sheet applied to dorsa of
hairless dogs accelerated wound closure and healing of
superficial and partial-thickness wounds [16]. Current chal-
lenges regarding the delivery of EGF at physiologically(iii) Macrophages express CSF-1, TNF-b and PDGF, which act as
chemoattractants for fibroblasts.
Proliferation:
(i) PDGF, TGF-b, and ECM molecules induce fibroblasts proliferation,
new ECM deposition, and integrin receptors expression for cellular
recognition and adherence.
Remodelling:
(i) Crosslinking of new collagen matrix.
(ii) Fibroblast-derived enzymes including collagenases, plasminogen
activator, and gelatinases create pathways through tightly woven
ECM for cellular movement.
(iii) Granulation tissue is replaced with an acellular, avascular scar.
641
(a) Wound at days 1–3
(b) Wound at days 3–10
(c) Wound at days 7–14
KeranocyteKey:
Migrang or
hyperproliferave
keranocyte
Mast cell
Macrophage
Neutrophil
Lymphocyte
Fibrin clot/scab
Blood vessel
Granulaon ssue
Late granulaon
ssue/early scar
Myoﬁbroblast
Fibroblast
Diﬀerenang
keranocyte
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Figure I. A schematic representation of the normal wound healing process incorporating various cell-signalling molecules [80].
Review Trends in Biotechnology December 2012, Vol. 30, No. 12relevant concentrations and durations still prevail due to its
rapid breakdown within the wound environment, encourag-
ing research into effective immobilisation and delivery tech-
niques. For example, biodegradable microspheres that
contain EGF provide sustained EGF delivery and hence
more effective wound healing in a rabbit dorsal skin wound
model [17]. Despite such encouraging results, supplemental
EGF has a mitogenic effect upon cells and has been impli-
cated in the spread of epithelial malignancies [18]. However,
the beneficial effects of EGF in the wound healing process
should not be denied, thus requiring further research.642Basic fibroblast growth factor (bFGF)
FGF comprises a large family of mitogens that are actively
involved in the processes of wound healing, embryonic
development, angiogenesis, and tumour progression [19–
21]. Both acidic fibroblast growth factor (aFGF) and bFGF
are found within the wound fluid at the earliest stages of
healing [22]. aFGF, like bFGF, is a potent mitogen and
chemoattractant for vascular endothelial cells, dermal fibro-
blasts, and epidermal keratinocytes. In the initial phases of
wound healing, bFGF participates by activating local macro-
phages and can still be identified within the healing tissue
Box 3. Management of thermal wounds
Thermal wounds have been divided into three zones of histopatho-
logical injury:
(i) Zone of coagulation (eschar): outermost area undergoes
complete and irreversible necrosis and denaturation of proteins.
(ii) Zone of stasis and oedema: partially denatured proteins and
slow blood flow.
(iii) Zone of hyperemia: gradually increasing blood flow.
In case of wound infection or poor perfusion, a seemingly
superficial burn may in time develop into a more severe and deeper
wound with necrotic areas extending into the zone of stasis.
Current treatment standards:
(i) Early and complete excision of eschar to prevent wound
infection.
(ii) Full-thickness burns: wound coverage with an autologous split-
thickness skin graft harvested from intact areas of the patient’s
skin.
If larger parts of the total body surface area have been damaged,
autologous skin grafts may still be taken and then meshed in order to
enlarge the size of the graft. The disadvantages of such practices are
morbidity, significant pain at the donor site, and the characteristic
corrugated scar as the recipient site heals. In cases of total or near-
total full-thickness skin injuries, donor sites may be unavailable,
necessitating the use of cadaveric skin to fulfil vital barrier functions.
Cadaveric skin grafts are lyophilised, thus removing the cellular
component to prevent graft immune rejection. They may either be
obtained from nonprofit skin banks or purchased as for example,
Karoskin. Such allografts represent temporary ‘bridging’ measures
for immediate wound coverage in the acute stages post-injury.
Disadvantages of utilising human cadaveric skin:
(i) Donor organ shortage and limited skin bank availability.
(ii) Moral objections from the patient’s or surgeon’s perspective.
(iii) Risk of viral transmission from cadaveric tissues to the
recipient.
There is an urgent need for fully synthetic, yet biocompatible and
so-called ‘smart’ skin bioconstructs for the regeneration of scar-free
skin.
Review Trends in Biotechnology December 2012, Vol. 30, No. 12during the remodelling phase that occurs several weeks
after injury [23]. bFGF accelerates neovascularisation as
shown in a rabbit ear wound healing model, in which
wounds supplemented with exogenous bFGF healed signifi-
cantly faster compared to untreated controls [24]. Radia-
tion-induced cutaneous wounds created in miniature pig
models treated with exogenous bFGF showed increased
dermoepidermal proliferation, new blood vessel formation,
higher overall mechanical skin stability, and adnexae in-
tegrity [25]. In 2001, genetically recombinant bFGF was
approved for clinical use in Japan under the trade name
Fiblast Spray (Kaken Pharmaceutical Co. Ltd., Tokyo,
Japan). Clinical trials conducted on second-degree burn
wounds in Japanese adults and children showed accelerated
rates of wound healing and superior mechanical properties
of the resultant scars when topical bFGF was initiated
relatively soon after creation of the burn injury (1–4 days,
mean 2 days) [26,27]. Despite such promising results, con-
cerns over the carcinogenic potential of topical FGF appli-
cation remain; bFGF has been identified as a major
autocrine stimulant in melanoma and, in combination with
UV light, is associated with tumour progression [28,29].
Further research is needed to corroborate existing evidence
of beneficial effects of bFGF on wound healing and refute any
associations with the progression of skin cancers.Keratinocyte growth factor (KGF)
KGF is expressed within the dermis and hypodermis below
the wound, whereas the KGF receptor is predominantly
found on epithelial cells of the epidermis, suggesting a
paracrine mediation of epithelial cell growth. Several ani-
mal and clinical studies have demonstrated the cytopro-
tective and epithelial regenerative properties of KGF [30–
32]. Such favourable effects depend on several mechanisms
including cell proliferation, migration, differentiation, sur-
vival, DNA repair, and detoxifying enzyme induction,
which collectively act to strengthen the integrity of the
epithelium [33]. During the initial 24 h of normal human
wound healing, KGF expression is upregulated 100-fold
and remains elevated for several days [34]. This upregula-
tion in KGF is significantly dampened in genetically dia-
betic and glucocorticoid-treated mice [35,36]. In a porcine
partial-thickness wound model, topical application of re-
combinant KGF demonstrated an accelerated rate of re-
epithelialisation compared to controls not receiving KGF
[37]. In a murine full-thickness wound healing model,
keratinocyte proliferation and angiogenesis were signifi-
cantly retarded in KGF knockouts compared to wild-type
mice [38]. These results suggest a further role of KGF in
the control of wound bed angiogenesis. However, the use of
KGF in epithelial cancer patients raises concerns regard-
ing potential tumourigenicity of KGF because epithelial
cells express KGF receptors. Several studies have identi-
fied a potential association between the overabundance of
KGF and tumour growth progression [39–41]. Further
studies are warranted to examine the nature and extent
of KGF involvement in tumour development.
Vascular endothelial growth factor (VEGF)
The VEGF family encompasses VEGF-A, VEGF-B, VEGF-
C, VEGF-D, and PlGF. During wound healing, VEGF-A is
highly expressed by keratinocytes within the wound bed to
promote new blood vessel formation essential for tissue
regeneration [42] and re-epithelialisation of wounds
[43,44]. VEGF is the major angiogenesis-promoting GF
due to its combined ability to stimulate endothelial cell
proliferation and migration [45], basement membrane
degradation [46], tubular and luminal structure formation
[47], increased vascular permeability [48], and new vessel
formation [49]. In a diabetic mouse model, minicircle plas-
mid DNA encoding VEGF was successfully transfected into
proliferating cells within wounded tissue, resulting in a
high level of VEGF expression [50]. Wound healing rates
were significantly accelerated in plasmid-exposed injuries
compared to those exposed to empty vehicles. Similarly,
vector-mediated VEGF transfer onto experimental murine
burn wounds increased angiogenesis as well as epithelial
proliferation and ECM maturation [51]. Despite extensive
evidence for accelerated wound healing via increased blood
vessel formation, the use of VEGF must be critically ap-
praised within the context of potential negative effects; two
relatively recent studies have reported associations be-
tween chronic burn injuries and the development of pri-
mary cutaneous anaplastic large cell lymphoma (PCALCL)
[52,53]. According to these reports, the growth of PCALCL
is fuelled by VEGF production and secretion by atypical
large lymphocytes. Furthermore, skin biopsies from the643
Review Trends in Biotechnology December 2012, Vol. 30, No. 12erythematous region surrounding the PCALCL have
revealed rich neovascularisation secondary to VEGF over-
expression. Although the differing effects of VEGF on
cutaneous wounds require a cautious approach, it seems
of equal importance to investigate its beneficial effects
further in order to avoid premature rejection of a poten-
tially useful GF.
Insulin-like growth factor-1 (IGF-1)
High levels of IGF-1 found within cutaneous wounds have
been shown to accelerate epidermal wound healing and
inhibit apoptosis pathways [54,55], whereas reduced ex-
pression of IGF-1 is associated with retarded wound heal-
ing [56]. For example, IGF-1 receptor knockout mice (IGF-
1r/) exhibited skin hypotrophy with fewer and smaller
hair follicles [57]. Wound healing by re-epithelialisation
was accelerated by local overexpression of IGF-1, whereas
no effects were observed on the underlying dermis [58]. In
vitro studies, however, have found evidence for the stimu-
latory effects of IGF-1 on collagen and ECM production
[59]. Similarly, wound beds of IGF-1-depleted rats had
significantly lower collagen content, as measured by the
amount of hydroxyproline, a major component of collagen,
compared to nondepleted animals, suggesting a reduced
capacity for wound healing. Subsequent IGF-1 infusion
returned concentrations to near-normal levels [60]. Such
contrasting evidence for a role in ECM and collagen pro-
duction is indicative of a dose-dependent activation of
dermal fibroblasts by IGF-1. In a porcine diabetic full-
thickness excisional wound model, transplantation of
IGF-1-transfected keratinocytes increased local IGF-1 ex-
pression 900-fold, leading to significantly accelerated ker-
atinocyte migration and wound closure [61]. Wound
contracture, a possible confounder in the interpretation
of wound closure rates, is not thought to have significantly
influenced the wound healing process, because degrees of
contractions were similar in transfected and control
groups. Maintenance of appropriate IGF-1 concentrations
within the wound bed is significantly important because
overexpression has been linked to skin hyperplasia and
tumour growth [62,63].
Platelet-derived growth factor (PDGF)
PDGF is involved throughout all stages of normal wound
healing. PDGF is released by degranulating platelets and
activated macrophages within the wound fluid. Later in
the proliferative stage, PDGF is responsible for the differ-
entiation of fibroblasts into their contractile phenotype,
the myofibroblasts which through attachments of their
filopodia to components of the ECM, drag or contract the
tissues together [64]. Several animal studies have demon-
strated accelerated wound closure in normal and patho-
physiological states when the wound bed was
supplemented with exogenous PDGF [65]. In a genetically
diabetic mouse model (C57BL/Ks-J-db/db), large full-
thickness skin wounds (1.51.5 cm2) created on the
mid-back were exposed to recombinant human PDGF
[66]. At 21 days, more fibroblasts, enhanced capillary
formation, and accelerated wound closure were observed
in treated diabetic mice compared to littermates receiving
empty vehicles. Furthermore, in vivo blockage of PDGF644receptors with the PDGFR-b inhibitor imatinib mesylate
resulted in delayed wound healing, reduced wound clo-
sure, and abnormal microvascular morphology, normally
observed in PDGFR-b/ mice, thus highlighting the piv-
otal role of PDGF in early wound healing [67]. However,
similar results could not be obtained using the same
animal model, same wound dimensions, but commercially
available Regranex [66]. In a recently published retrospec-
tive clinical study on the healing efficiency of supplemen-
tary PDGF on diabetic heel ulcers larger than 4 cm (an
independent predictor of limb loss), some beneficial effects
were observed when the standard treatment regime (dis-
tal femoral bypass surgery, partial calcanectomy, intra-
operative negative pressure wound treatment) was
boosted with PDGF [68]. PDGF is thought to modulate
beneficially the ulcer microenvironment, thereby acceler-
ating wound healing and closure. However, the small
cohort, lack of randomisation and blinding, as well as
the absence of a control population minimise the signifi-
cance of these results.
Transforming growth factor-b (TGF-b)
TGF-b exists in three isoforms – TGF-b1, TGF-b2, and
TGF-b3 – which are all involved in the process of wound
healing. After acute injuries, TGF-b1 is highly expressed
by keratinocytes, platelets, monocytes, fibroblasts, and
macrophages [69]. TGF-b acts in both autocrine and
paracrine manners, inducing its own synthesis by target
cells and activating nearby cells to synthesise and release
other GFs involved in the healing process [70]. The
autocrine action of TGF-b1 by fibroblasts sustains their
activity beyond the initial inflammatory stimulus [71]
and is postulated to play a key role in myofibroblast
differentiation [72]. TGF-b2 expression is related to
wound contracture and excessive collagen deposition,
but has also been demonstrated to be a causative factor
in scar formation [73]. Early foetal skin is well known for
its ability to regenerate wounds completely without the
formation of scar tissue, which is thought to be largely
associated with a significantly reduced expression of
TGF-b1, coinciding with highly elevated levels of TGF-
b3 [74]. As described within Box 4 on foetal wound
healing, the exact underlying mechanism of action for
scarless foetal wound regeneration has not been elucidat-
ed so far, leaving the respective roles of the TGF-b iso-
forms to be fully uncovered.
The results obtained with the use of GFs to accelerate
wound healing, while encouraging on both experimental
and clinical levels, must be interpreted cautiously, because
the same factors are often implicated in exuberant tissue
and tumour growth. More basic and preclinical research is
necessary to indicate when GF concentration moves from
being beneficial to becoming potentially harmful. Such
ambiguous circumstances demand careful evaluation for
more than one reason.
First, it is of paramount importance that exposure to
inappropriate amounts of GFs is prevented due to poten-
tially carcinogenic tendencies in vivo, as previously men-
tioned. Any such long-term adverse effects must be
excluded prior to commencing clinical trials. Only a few
of the numerous GFs playing their part throughout the
Box 4. Foetal wound healing
(i) Intrinsic and complete self-regeneration without scar formation
attributable to different healing mechanisms.
(ii) The inflammatory response is significantly reduced with fewer
differentiated inflammatory cells in early gestational foetal
wounds.
(iii) Higher numbers of phagocytic cells and morphogenic factors
and collagen deposition resembling that of normal skin (i.e.,
large bundles of ECM in a normal reticular orientation as
opposed to an adult-pattern abnormal deposition of parallel
bundles of mainly collagen types I and III).
(iv) Scarless healing is only possible during the first two trimesters,
attributable to a finely orchestrated interplay between several
factors:
a. Early reticular collagen deposition.
b. Reduced inflammatory response.
c. Higher levels of HA.
d. Altered ratios of signalling molecules and genes.
(v) During the third trimester, a transition occurs and the skin loses
its ability to regenerate, resulting in the formation of fibrous
scar tissues.
Previous assumptions that the sterile, GF-enriched intrauterine
environment is the determining factor for scarless healing have been
refuted by several seminal studies; a marsupial model for cutaneous
healing demonstrated that the developing opossum retained its
ability for scarless regeneration despite growing in a pouch devoid of
amniotic fluid [36]. Transplantation studies on sheep models have
shown that wounded adult or late foetal skin transplanted onto early-
gestation foetal lambs healed with scar formation [37], whereas
wounded early foetal human skin transplanted into nude mice
regenerated with no scar formation [38]. This demonstrates indepen-
dence from environmental factors and an intrinsic ability for early-
gestational foetal skin to regenerate without scar formation.
The complete elucidation of the intrinsic foetal wound healing
mechanisms would allow for the meticulous re-establishment of
signalling events within an ex-foetal environment, resulting in
scarless dermal regeneration in adult wounds.
Box 5. Stem cell-seeded skin regeneration scaffolds
Slow scaffold vascularisation is a critical limiting factor in skin
wound regeneration due to inadequate supplies of nutrients and
oxygen and a build-up of waste products within the tissues. SCs
have the ability to self-renew and differentiate into lineage-specific
progenies. Despite their ability to acquire any cell type of an
organism, embryonic SC usage is retarded by ethical considera-
tions. Adult SCs, on the other hand, have several advantages: (i) the
ability to differentiate into several lineages within a tissue; (ii) the
relative ease of access; and (iii) less stringent regulatory concerns
and a higher degree of public acceptance compared to embryonic
SC use. The beneficial effects of adult mesenchymal stem cells
(MSCs) in wound bed neovascularisation and accelerated healing
has been demonstrated in several preclinical models [87,88]. Yet,
the mechanisms of action remain elusive; evidence for paracrine
signalling subsists [89], although the role of MSC differentiation in
wound healing is less clear, partially due to low engraftment
efficiency of cells [90]. Thus, cell delivery vehicles have been applied
to provide suitable cellular microenvironments and enhanced
engraftment, survival and differentiation into appropriate mature
cells [87] (see Figure 1 in main text). Particular emphasis is placed on
the integration of human adipose derived stem cells (hADSCs) into
skin regeneration scaffolds due to their accessibility and facile in
vitro expansibility. hADSCs are a source of MSCs that have shown a
potential for therapeutic vascularisation due to the production of
angiogenic GFs [91]. This was demonstrated in an in vivo wound
healing study using nude mice; two identical defects were created in
the dorsal skin of mice and exposed to either collagen gel preseeded
with hADSCs or empty collagen vehicles [92]. Angiogenic GF
production was significantly enhanced in SC-seeded wounds
compared to nonseeded wounds. Another study obtained similar
results with ADSCs-impregnated microcarrier systems [93]. Despite
substantial preclinical evidence for a beneficial role of SCs in the
wound healing process, one should approach the clinical use of
MSCs cautiously because evidence suggests a contributing role in
cancer SC maintenance [94]. It remains to be seen how useful SC
technology proves to be in clinical reality; the tendency to overplay
the role of SCs for regenerative purposes, however, should not
discourage scientists to evaluate further the substantial potential
within the field of regenerative SC technology.
Review Trends in Biotechnology December 2012, Vol. 30, No. 12process of wound healing are FDA approved and clinically
available for the purpose of accelerating wound repair (e.g.,
Regranex, Kepivance). One may argue that worries about
lasting adverse effects of GF use in the context of skin
wound healing may be unfounded because their applica-
tion is mostly local. Furthermore, GFs are rapidly degrad-
ed into natural metabolites by the wound fluid, thus
eliminating any downstream effects. Such rapid elimina-
tion from the body is, however, avoidable via encapsulation
techniques, enabling GFs to linger within the wound for
longer prolonging their trophic effects.
Second, determining beneficial effects on wound heal-
ing is ongoing. Selective GF treatment leads to accelerated
rates of healing both in experimental and preclinical
trials. Potential reasons for failure might be inappropriate
routes of GF delivery or overabundance of GFs that cancel
out the anticipated beneficial effects on wound healing.
This, again, demonstrates the critical need to investigate
the optimal GF concentrations to stimulate appropriately
skin regeneration while avoiding the risk of overstimula-
tion and tumour formation or receptor downregulation.
Box 5 provides a critical discussion on the benefits
and disadvantages of SC usage for tissue engineering
purposes.Nanoengineered scaffolds for a bottom-up approach to
wound regeneration
Regenerative medicine aims at recuperating lost tissues
by guiding cell growth and restoring original tissue archi-
tecture. This requires the presence of a scaffold because
isolated cells are unable to re-establish their native struc-
tures due to a lack in extracellular guidance. Figure 1
shows a schematic representation of the ideal skin regen-
eration scaffold. Although various scaffolds for skin re-
generation are already on the market (Table 1), their
clinical implementation remains riddled with flaws, rang-
ing from poor take rates [75] and poor cosmesis to rela-
tively high infection rates. Efforts at increasing their
effectiveness include bioactivation, that is, expanding
their role from being a simple structural framework to a
delivery vehicle for GFs, cytokines, or genes [76,77]. In this
way, tissue regeneration can be actively promoted rather
than merely passively suggested. This should, however,
not discourage research into more suitable scaffold archi-
tectures, because accumulating evidence highlights the
importance of biocompatible scaffold materials, appropri-
ate pore sizes, and cell-growth-promoting surface topo-
graphies [78,79]. Although scientists agree on the
importance of the extracellular microarchitecture for cell645
Review Trends in Biotechnology December 2012, Vol. 30, No. 12adherence and proliferation, studies have shown an
abnormally elongated phenotype when cells were grown
on microfibrous materials. Cells cultured on nanofibrous
structures, however, demonstrated a phenotype resem-
bling that of cells growing within natural environments.
This may be explained by the close architectural approxi-
mation of nanofibrous materials to natural ECM and
collagen fibrils, which themselves exhibit nanometre
dimensions. Thus, a natural cell environment can be
feigned and cells guided along normal morphogenic lines.
Additionally, natural ECM fibrils serve as storage vehicles
for SCs and bioactive factors to regulate cell migration,
proliferation, and differentiation. The bottom-up ap-
proach allows for tight control over scaffold micro- and
nanoarchitecture, porosity, as well as the sequential in-
corporation of bioactive elements which, in turn, influence
cellular interactions via the creation of a beneficial biomi-
metic micro- and nanoenvironment.
Concluding remarks and future perspective
The burden of cutaneous wounds is immense in both
personal and financial terms. Clinically available and
feasible treatment strategies are still lacking despiteBurn wound 
Coagulated
Scaﬀold  
Figure 1. Schematic representation of the ideal scaffold to promote skin regeneratio
proposed schematic has not been developed successfully yet. Abbreviations: AgNPs, s
646various skin substitutes being under thorough investiga-
tion. The emergence of nanotechnology combined with the
latest SC technology and the ever-increasing appreciation
of cell-signalling pathways in both adult and foetal wound
healing models have opened up new avenues for precise
biotechnological wound bed manipulations for accelerated
healing. Cutting-edge developments within the area of
tissue-engineered scaffolds lead the way into a new era
of organ consciousness with the ultimate goal of tissue
regeneration rather than replacement.
Approved treatment strategies for skin wounds mostly
aim to replace lost tissues rather than support intrinsic
self-healing mechanisms. Technological advances now
grant scientists the ability to manipulate precisely scaffold
materials and engineering strategies within nanometre
dimensions to create nanotopographies that mimic the
natural ECM. The incorporation of SCs, GFs, and nano-
particles into scaffolds promotes the intricate interplay
between naturally occurring cell-signalling factors to
achieve full tissue regeneration. With such fast and cur-
rent developments in nanotechnology and biomedical
sciences, we are continuously improving skin regeneration
and repair. The future trend of regenerative medicine inBacteria 
AgNPs
GFs 
TRENDS in Biotechnology 
n. Despite intense research efforts aiming at optimising available scaffolds, the
ilver nanoparticles; GFs, growth factors.
Review Trends in Biotechnology December 2012, Vol. 30, No. 12general, and tissue-engineering of skin in particular lies in:
(i) the comprehension of intricate intercellular biochemical
communications; (ii) the engineering of scaffold structures
on a micro- and nanodimension; and (iii) the integration of
GFs and SCs into such scaffolds to obtain a bioactive
cocktail capable of active guidance in skin regeneration.
Despite the presence of realistic benefits and dangers
associated with GF or SC supplementation, ongoing re-
search into their exploitation is fundamental if regenera-
tive medicine is to have a future.
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